2 december 2017: klik op de titel

Key Points

  • In patients with triple-negative breast cancer, an absolute increase in the estimated pathologic complete response rate of 40% was observed in the pembrolizumab arm.
  • In patients with HER2-negative breast cancer, an absolute increase in the estimated pathologic complete response rate of 30% was observed in the pembrolizumab arm.
  • In patients with hormone receptor–positive/HER2-negative breast cancer, an absolute increase in the estimated pathologic complete response rate of 21% was observed in the pembrolizumab arm.

Gerelateerde artikelen
 

Gerelateerde artikelen

Atezolizumab + nab-paclitaxel >> sTILs - tumor infiltrating >> Vrouw met uitgezaaide hormoongevoelige >> Pertuzumab - Perjeta door >> ASCO 2017: I-SPY 2 Trial: >> Immuuntherapie voor borstkanker >> Immuuntherapie tegen borstkanker >> Nivolumab: Immuuntherapie >> Vaccin GP2 naast herceptin >> Olaparib plus cedinarib lijkt >>